Martínez Santana, VirginiaRodríguez Murphy, EstherSmithson Amat, AlejandroMiserachs Aranda, NuriaRío-Gil, Ruben delTorre Lloverás, Inmaculada2021-03-102021-03-102017-05-202047-9956https://hdl.handle.net/2445/174864Background: The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown. Case report: We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis. Conclusion: This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.4 p.application/pdfeng(c) European Association of Hospital Pharmacists, 2018Hepatitis CMalalties autoimmunitàriesInteraccions dels medicamentsHepatitis CAutoimmune diseasesDrug interactionsinfo:eu-repo/semantics/article7080192021-03-10info:eu-repo/semantics/openAccess31156986